Immune checkpoint inhibition by anti-PDCD1 (anti-PD1) monoclonal antibody has significant therapeutic activity against central nervous system lymphoma in an immunocompetent preclinical model

Br J Haematol. 2018 Nov;183(4):674-678. doi: 10.1111/bjh.15009. Epub 2017 Oct 26.

Authors

Yushi Qiu¹, Zhimin Li¹, Frederic Pouzoulet², Prakash Vishnu³, John A Copland 3rd¹, Keith L Knutson⁴, Carole Soussain², Han W Tun^{1

3}

Affiliations

¹ Department of Cancer Biology, Mayo Clinic, Jacksonville, FL, USA.
² Department of Hematology, Rene-Huguenin Hospital-Curie Institute, Saint Cloud, France.
³ Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL, USA.
⁴ Department of Immunology, Mayo Clinic, Jacksonville, FL, USA.

PMID: 29076134
DOI: 10.1111/bjh.15009

No abstract available

Keywords: CD274 (PD-L1); PDCD1LG2 (PD-L2); anti-PDCD1 (anti-PD1); primary central nervous system lymphoma (PCNSL); survival.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Antineoplastic Agents, Immunological / pharmacology*
Central Nervous System Neoplasms* / drug therapy
Central Nervous System Neoplasms* / immunology
Central Nervous System Neoplasms* / pathology
Humans
Lymphoma* / drug therapy
Lymphoma* / immunology
Lymphoma* / pathology
Mice
Neoplasm Proteins / antagonists & inhibitors*
Neoplasm Proteins / immunology
Neoplasms, Experimental* / drug therapy
Neoplasms, Experimental* / immunology
Neoplasms, Experimental* / pathology
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
Programmed Cell Death 1 Receptor / immunology

Substances

Antineoplastic Agents, Immunological
Neoplasm Proteins
Pdcd1 protein, mouse
Programmed Cell Death 1 Receptor